Impact of the number of prior systemic treatment lines on lenvatinib and pembrolizumab combination therapy for advanced or recurrent endometrial cancer:Experience from a single institution in Japan with 21 cases

DOI Web Site

Bibliographic Information

Other Title
  • 進行再発子宮体癌に対するレンバチニブ・ペムブロリズマブ併用療法における 前治療レジメン数は治療効果に影響するのか～単施設における21例の使用経験から～
  • シンコウ サイハツ シキュウタイ ガン ニ タイスル レンバチニブ ・ ペムブロリズマブ ヘイヨウ リョウホウ ニ オケル ゼン チリョウ レジメンスウ ワ チリョウ コウカ ニ エイキョウ スル ノ カ : タンシセツ ニ オケル 21レイ ノ シヨウ ケイケン カラ

Search this article

Description

Lenvatinib and pembrolizmab combination therapy (Lp therapy) remains the preferred second-line therapy for platinum-resistant advanced or recurrent endometrial cancer. However, limited data exist on its efficacy in later treatment lines. We retrospectively analyzed 21 patients who received Lp therapy at our department. Cases were subsequently divided into two groups: the 1 . 2L group (one or two prior regimens) and 3L group (three or more regimens). The median follow-up period for all patients was 9.3 months. The objective response rate (ORR) was 43&, and the median progression-free survival (PFS) was not reached. Among the 21 cases, 8 were in the 3L group (38&). No significant differences in ORR (median, 30& vs. 63&) and PFS (median, not reached vs. 11.4 months) were observed between the two groups. The most common adverse events of any grade were hypertension (81&) and thyroid dysfunction (hypothyroidism 62& and hyperthyroidism 29&), with serious adverse events occurring in 6 cases (immune checkpoint inhibitors related myocarditis, tumor infection, acute cholecystitis, gastrointestinal perforation, and intestinal fistula). No significant differences in the incidence of adverse events were noted between the two groups. Overall, we found that Lp therapy was effective regardless of the number of prior regimens. 〔Adv Obstet Gynecol, 76(3): 222-228, 2024(R6.8)〕

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top